Access DB# 40715

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Natalie Davis Examiner #: 78462 Date: 4-23-01
Art Unit: 1642 Phone Number 308-6410 Serial Number: 09/717883
Mail Box and Bldg/Room Location: 8E12 CM1 4C01 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: 11-22-99

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Please search Ovr107 for its use in the diagnosis, staging, monitoring + treatment of cancers. Also, an antibody to Ovr107. ~~Also Seq ID NO: 1~~ cancelled no CRF data

RECEIVED APR 23 2001 TECH CENTER 1600/2900

nothing in get pat. info, no pat. no. in Palm

email 4/26 SPP

****

STAFF USE ONLY

Searcher: ~~Point of Contact:~~
Searcher Phone #: Alex Waclawiw
Searcher Location: Technical Info. Specialist CM1 12C14 Tel: 308-4491
Date Searcher Picked Up: 5-3
Date Completed: 5-3
Searcher Prep & Review Time: 8
Clerical Prep Time: _____
Online Time: 31

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) _____
Bibliographic /
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN 1 2.1
Dialog 10
Questel/Orbit 31
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) _____

PTO-1590 (1-2000)

```
HILIGHT set on as ''
HILIGHT set on as ''
?
       03may01 13:51:42 User035515 Session D451.2
            $0.00    0.056 DialUnits File410
     $0.00  Estimated cost File410
     $0.00  Estimated cost this search
     $0.66  Estimated total session cost   0.229 DialUnits
SYSTEM:HOME
Menu System II: D2 version 1.7.8.term=ASCII
                    *** DIALOG HOMEBASE(SM) Main Menu ***

 Information:
  1.  Announcements (new files, reloads, etc.)
  2.  Database, Rates, & Command Descriptions
  3.  Help in Choosing Databases for Your Topic
  4.  Customer Services (telephone assistance, training, seminars, etc.)
  5.  Product Descriptions

 Connections:
  6.  DIALOG(R) Document Delivery
  7.  Data Star(R)

    (c) 2000  The Dialog Corporation plc      All rights reserved.

      /H = Help            /L = Logoff          /NOMENU = Command Mode


Enter an option number to view information or to connect to an online
 service.  Enter a BEGIN command plus a file number to search a database
(e.g., B1 for ERIC).
? b 411


       03may01 13:51:53 User035515 Session D451.3
            $0.00    0.164 DialUnits FileHomeBase
     $0.00  Estimated cost FileHomeBase
     $0.01  TYMNET
     $0.01  Estimated cost this search
     $0.67  Estimated total session cost   0.394 DialUnits
File 411:DIALINDEX(R)

DIALINDEX(R)
   (c) 2001 The Dialog Corporation plc

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
? sf all

   You have 576 files in your file list.
   (To see banners, use SHOW FILES command)
? s ovr107 or ovr()107


Your SELECT statement is:
  s ovr107 or ovr()107
```

Items	File
Examined 50	files
Examined 100	files
Examined 150	files
Examined 200	files
Examined 250	files
Examined 300	files
Examined 350	files
Examined 400	files
Examined 450	files
Examined 500	files
Examined 550	files

No files have one or more items; file list includes 576 files.

=> d his

(FILE 'WPIDS' ENTERED AT 14:27:14 ON 03 MAY 2001)
DEL HIS Y

FILE 'MEDLINE, BIOSIS, WPIDS, EMBASE' ENTERED AT 14:29:11 ON 03 MAY 2001

L1 0 S OVR107
L2 0 S OVR 017
L3 105 S OVR
L4 106461 S (CANCER OR TUMOR OR TUMOUR) (L) MARKER#
L5 0 S L3 AND L4
L6 3080636 S (CANCER OR TUMOR OR TUMOUR OR NEOPLAS?)
L7 3 S L6 AND L3
L8 3 DUP REM L7 (0 DUPLICATES REMOVED)

=> d bib ab 1-3

L8 ANSWER 1 OF 3 MEDLINE
AN 2000172713 MEDLINE
DN 20172713 PubMed ID: 10707722
TI Distal fibular giant cell **tumour**.
AU Dogra A S; Kulkarni S S; Bhosale P B
CS Department of Orthopaedics, Seth G S Medical College, Parel, Mumbai.
SO JOURNAL OF POSTGRADUATE MEDICINE, (1995 Jul-Sep) 41 (3) 83-4.
Journal code: JS7; 2985196R. ISSN: 0022-3859.
CY India
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200003
ED Entered STN: 20000330
Last Updated on STN: 20000330
Entered Medline: 20000323
AB A patient who reported with a slowly growing swelling **ovr** thee lateral aspect of the left ankle, was investigated and diagnosed to have a
giant cell **tumour** which was confirmed on FNAC. The **tumour** was managed with excision biopsy and reconstruction. The case is being reported for its rare site of occurrence.

L8 ANSWER 2 OF 3 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1993-182210 [22] WPIDS
DNC C1993-080645
TI Extending vascular dwell time of therapeutic and diagnostic agents - by adjunct admin. with dwell time enhancing agent.
DC B05 B07 D16
IN LONG, D M; LONG, R A
PA (LONG-I) LONG D M; (LONG-I) LONG R A
CYC 38
PI WO 9309762 A2 19930527 (199322)* EN 62p
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA SE
W: AU BB BG BR CA CS FI HU JP KR LK MG MN MW NO PL RO RU SD UA
AU 9230712 A 19930615 (199340)
US 5264220 A 19931123 (199348) 16p
EP 612240 A1 19940831 (199433) EN

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE
US 5391376 A 19950221 (199513) 17p
WO 9309762 A3 19930624 (199513)
JP 07505127 W 19950608 (199531)
EP 612240 A4 19950517 (199615)
US 5679394 A 19971021 (199748) 15p
ADT WO 9309762 A2 WO 1992-US9660 19921112; AU 9230712 A AU 1992-30712 19921112; US 5264220 A US 1991-790855 19911112; EP 612240 A1 EP 1992-924382 19921112, WO 1992-US9660 19921112; US 5391376 A Div ex US 1991-790855 19911112, US 1993-122192 19930915; WO 9309762 A3 WO 1992-US9660 19921112; JP 07505127 W WO 1992-US9660 19921112, JP 1993-509361 19921112; EP 612240 A4 EP 1992-924382 ; US 5679394 A Div ex US 1991-790855 19911112, Div ex US 1993-122192 19930915, US 1995-379249 19950127
FDT AU 9230712 A Based on WO 9309762; EP 612240 A1 Based on WO 9309762; US 5391376 A Div ex US 5264220; JP 07505127 W Based on WO 9309762; US 5679394
A Div ex US 5264220, Div ex US 5391376
PRAI US 1991-790855 19911112; US 1993-122192 19930915; US 1995-379249 19950127
AB WO 9309762 A UPAB: 19931115
Method for deliverng a particulate therapeutic or diagnostic agent (PTDA) via the vascular compartment of a mammal, comprising the adjunct admin. of
the above agent and a vascular dwell-time enhancing agent (VDTEA), provided that the PTDA is not a particulate blood substitute (PBS), is new.

Method for delivering a PBS via the vascular compartment of a mammal,
comprising the adjunct admin. of the PBS and VDTEA, is new.

Method for preventing or treating cachexia in a mammal, comprising admin. of an anti-cachexia agent, is new.

USE/ADVANTAGE - The VDTEA retard phago- and pino-cytosis, which causes removal of the PTDA by metabolism and excretion via the RES, so that the time that agents can express their efficiency is increased. Side-effects traceable to phagocytosis causing cytokine and eicosanoid (TNF, IL-1, PGE-2, thromboxane A-2) release are also reduced e.g, fever, back pain, and pulmonary hypertension. Phagocytosis is esp. marked for particulates of 0.001-50 microns dia. The VDTEA also enhance the stability, of the carrier system used for the agent, retarding metabolisation. Therapeutic particulates include chemotherapeutic agents, vasopressors, antiinflammatories, anaesthetics, vasodilator, tranquilliser, soporific, or sedatives, provided. Uses of VDTEA with PBS include prevention and treatment of hypoxia in non-**neoplastic** cell (e.g, during any surgical procedure with compromised blood circulation and perfusion, including angioplasty or heart-lung by-pass), other hypoxia, or anaemia. A partic. use is in treatment of **neoplastic** tissue, in which the tissue need not be immediately irradiated, e.g, **ovr** 3 hr., pref. up to 48-72 hr. after the adjunct admin.
Dwg.0/0

L8 ANSWER 3 OF 3 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1989:478708 BIOSIS
DN BA88:114468
TI **CANCER** MORTALITY IN A NORTHERN ITALIAN COHORT OF RUBBER WORKERS.
AU NEGRI E; PIOLATTO G; PIRA E; DECARLI A; KALDOR J; LA VECCHIA C

CS MARIO NEGRI, INST. PHARMACOLOGICAL RES., 20157 MILAN, ITALY.
SO BR J IND MED, (1989) 46 (9), 624-628.
CODEN: BJIMAG. ISSN: 0007-1072.
FS BA; OLD
LA English
AB An analysis of the mortality of a cohort of 6629 workers employed from 1906 to 1981 in a rubber tire factor in northern Italy (978 deaths and over 133,000 man-years at risk) showed that the all cause mortality ratio was slightly lower than expected (0.91). Overall **cancer** mortality was close to expected (275 v 259.4) but there were significant excess rates for two **cancer** sites: pleura (9 observed v 0.8 expected, which may be due to the use of fibre containing talc) and bladder (16 observed v 8.8 expected). Death rates were not raised for other sites previously associated with employment in the rubber industry, such as cancers of the lung and brain, leukaemias, or lymphomas. The substantially reduced relative risk of pleural **cancer** among workers first employed after 1940 (RR = 0.05 compared with before 1940) probably reflected improvements in working conditions over more recent periods. For **cancer** of the bladder, the relative risk was also lower for workers first engaged after 1940. Thus no appreciable risk for any disease was apparent for workers employed **ovr** the past four decades. Analysis for each of the 27 job categories showed a substantial excess for **cancer** of the pleura in the mechanical maintenance workers (4 observed v 0.17 expected); an excess of **cancer** of the lung (21 v 13.48) was also present in this job category.

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:35:07 ON 03 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 3 May 2001 VOL 134 ISS 19
FILE LAST UPDATED: 2 May 2001 (20010502/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d his 19-

(FILE 'MEDLINE, BIOSIS, WPIDS, EMBASE' ENTERED AT 14:29:11 ON 03 MAY 2001)

FILE 'HCAPLUS' ENTERED AT 14:33:22 ON 03 MAY 2001
SET SFIELD BI
L9 0 S OVR107 OR OVR 107
L10 18 S OVR
L11 581450 S CANCER# OR TUMOR# OR NEOPLAS? OR METAST? OR MARKER#
L12 2 S L10 AND L11

FILE 'HCAPLUS' ENTERED AT 14:35:07 ON 03 MAY 2001

=> d .ca 1-2

L12 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:161492 HCAPLUS
DOCUMENT NUMBER: 132:204018
TITLE: Diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment
INVENTOR(S): Salceda, Susana; Sun, Yongming; Recipon, Herve; Cafferkey, Robert
PATENT ASSIGNEE(S): Diadexus Llc, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012758	A1	20000309	WO 1999-US19655	19990901

W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1998-98880 19980902

AB The present invention provides a new method for detecting, diagnosing, monitoring, staging, and prognosticating selected **cancers** including gynecol. **cancers** such as breast, ovarian, uterine and endometrial **cancer** and lung **cancer** by measurement of the levels of **cancer**-specific genes (CSG) in cells, tissue, or bodily fluid of a control patient and in a **cancer** patient, where elevated CSG levels indicated the presence of **cancer**, and further elevated levels the occurrence of **metastasis**. **Cancer**-specific gene sequences are presented which may be used as diagnostic **markers** for the presence of CSG. Antibodies to these sequences labeled with paramagnetic ions or radioisotopes may be used for imaging the **cancer**, and antibodies cojugated to cytotoxic agents may be used therapeutically.

IC ICM C12Q001-68
ICS C07K016-8
CC 3-1 (Biochemical Genetics)
Section cross-reference(s): 14

ST diagnosis staging imaging **cancer** CSG gene detection antibody
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence)
(CSG; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence)
(**Ovr**; **cancer marker**; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Antitumor agents
(anti-CSG conjugates; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Antibodies
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(anti-CSG; labeled and cytotoxin-conjugated; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT DNA sequences
Lung, **neoplasm**
Neoplasm
Ovary, **neoplasm**
Tumor markers
(diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Uterus, **neoplasm**
(endometrium; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT **Neoplasm**
(**metastasis**; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Diagnosis
(mol.; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Mammary gland
(**neoplasm**; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT 197982-63-1
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence)
(amino acid sequence; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)

IT 198056-06-3, GenBank U75329
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence)
(diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
IT 260425-01-2 260425-02-3 260425-03-4 260425-04-5 260425-05-6, DNA (human **cancer**-specific gene 255687) 260425-06-7, DNA (human **cancer**-specific gene 251313) 260425-07-8, DNA (human **cancer**-specific gene 12029) 260425-08-9, DNA (human **cancer**-specific gene 251804) 260425-09-0 260425-10-3 260425-11-4 260425-12-5 260425-13-6
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence)
(nucleotide sequence; diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment)
REFERENCE COUNT: 3
REFERENCE(S): (1) Croce; US 5939258 A 1999 HCAPLUS
(2) Paoloni-Giacobno; Genomics 1997, V44, P309
(3) Yu; US 5733748 A 1998 HCAPLUS

L12 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:650895 HCAPLUS
TITLE: Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung **cancer**
AUTHOR(S): Ohune, Terumasa; Fujiwara, Yasuhiro; Sumiyoshi, Hidetaka; Yamaoka, Naoki; Yamakido, Michio
CORPORATE SOURCE: Department Internal Medicine, Hiroshima Univ. School Medicine, Hiroshima, 734, Japan
SOURCE: Jpn. J. Cancer Res. (1995), 86(5), 490-500
CODEN: JJCREP; ISSN: 0910-5050
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Twenty-eight patients with inoperable or relapsed lung **cancer** were given a combination of oral etoposide, administered once a day at doses ranging from 40 to 60 mg/m2/day (d) for 21 consecutive days, and carboplatin, administered i.v. **ovr** 1 h at dose ranging from 300 to 400 mg/m2 on day 1 to det. the appropriate doses of this combination. In addn., pharmacokinetic and pharmacodynamic analyses were performed. All the patients had a performance status of 0 to 1. Serum etopside and free platinum (Pt) concns. were meausred using high-performance liq. chromatog. and at. absorption, resp. Myelosuppression, nausea and vomiting were the dose limiting toxicities of the schedule. The max. tolerated dose (MTD) was 50 mg/m2/d oral etoposide for 21 days and 400 mg/m2 i.v. carboplatin on day 1. For heavily pretreated patients, the MTD was 40 mg/m2/d oral etopside for 21 days and 350 mg/m2 i.v. carboplatin on day 1. No cumulative increase in the area under the concn.-time curve (AUC) for oral etoposide over time was obsd. There were significant correlations between the free Pt serum level (6, 8, 12, 24 h post-dose) and etoposide AUC level (days 1, 10 and 21) for graded hematol. toxicity,

and the percentage decrease and nadir counts of Hb, leukocytes, neutrophils and platelets. Several pharamacodynamic models were developed to predict the hematol. toxicity. In order facilitate pharmacodynamic evaluation in future studies, a limited sampling model for oral etoposide was also developed and validated.

```
=> fil reg

FILE 'REGISTRY' ENTERED AT 14:37:59 ON 03 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:     2 MAY 2001  HIGHEST RN 334473-38-0
DICTIONARY FILE UPDATES:    2 MAY 2001  HIGHEST RN 334473-38-0

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Structure search limits have been increased.  See HELP SLIMIT
for details.

=> d his


     (FILE 'REGISTRY' ENTERED AT 14:36:43 ON 03 MAY 2001)
                DEL HIS Y
L1             0 S OVR107
L2             2 S OVR
L3             1 S 21238[illegible]

     FILE 'REGISTRY' ENTERED AT 14:37:59 ON 03 MAY 2001

=> d ide can l2


L2   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2001 ACS
RN   21238[illegible]  REGISTRY
CN   OVR 1 (9CI)  (CA INDEX NAME)
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
               1 REFERENCES IN FILE CA (1967 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  129:217946


=> d ide can l2 2


L2   ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2001 ACS
RN   8056-51-7  REGISTRY
CN   18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-,
     (17.alpha.)-(.+-.)-, mixt. with (17.alpha.)-19-norpregna-1,3,5(10)-trien-
     20-yne-3,17-diol (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
```

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17.alpha.)-, mixt. contg. (9CI)
OTHER NAMES:
CN 17.alpha.-Ethynylestradiol-norgestrel mixt.
CN Biphasil
CN dl-Norgestrel-ethinylestradiol mixt.
CN dl-Norgestrel-ethynylestradiol mixt.
CN Duoluton
CN Ediwal
CN Ethinylestradiol-dl-norgestrel mixt.
CN Ethinylestradiol-norgestrel mixt.
CN Ethinylestradiol-norgestrel mixture
CN Ethynylestradiol-dl-norgestrel mixture
CN Ethynylestradiol-norgestrel mixt.
CN Ethynylestradiol-norgestrel mixture
CN Eugynon
CN Eugynon 30
CN Femenal
CN Follimin
CN Follinett
CN Follinyl
CN Gravistat
CN Lo-Femenal
CN **Lo/Ovral**
CN Microvlar
CN Microvlar 30
CN Minidril
CN Minigynon
CN Neogynon
CN Neovletta
CN Nordiol
CN Norgestrel-ethynylestradiol mixt.
CN Orasecron
CN Ovidon
CN **Ovral**
CN **Ovral 21**
CN **Ovral 28**
CN **Ovral L**
CN Ovran
CN Ovranette
CN Primovlar
CN Pro-Duosterone
CN Rigevidon
CN Sequilar
CN Sequilarum
CN Sequostat
CN SH 71121
CN SHB 261AB
CN SHB 264AB
CN Stediril
CN Stediril d
CN Triovlar
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS STEREOSEARCH
DR 8063-84-1, 8064-50-4, 70208-30-9
MF C21 H28 O2 . C20 H24 O2

CI MXS
LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMLIST, CIN, DIOGENES, EMBASE, IMSDIRECTORY, MEDLINE, PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 6533-00-2
CMF C21 H28 O2

Relative stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



467 REFERENCES IN FILE CA (1967 TO DATE)
467 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:359337

REFERENCE 2: 133:84410

REFERENCE 3: 133:68916

REFERENCE 4: 133:38394

REFERENCE 5: 133:935

REFERENCE 6: 132:132773

REFERENCE 7: 130:90626

REFERENCE 8: 130:33166

REFERENCE 9: 129:286116

REFERENCE 10: 128:188700

=> d all l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN **212384-33-3** REGISTRY
CN OVR 1 (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1

AN 129:217946 CA
TI Modeling of heat and mass transfer in intumescent fire-resistant coatings
AU Zverev, V. G.; Gol'din, V. D.; Nesmelov, V. V.; Tsimbalyuk, A. F.
CS Tomsk. Gos. Univ., Tomsk, 634050, Russia
SO Fiz. Goreniya Vzryva (1998), 34(2), 90-98
CODEN: FGVZA7; ISSN: 0430-6228
PB Izdatel'stvo Sibirskogo Otdeleniya RAN
DT Journal
LA Russian
CC 42-4 (Coatings, Inks, and Related Products)
AB Heat transfer, mass transfer, and properties of a series of intumescent coatings was studied. Exptl. data are given on the wt. loss and degree of swelling of these materials as a function of temp. The mechanisms of fireproofing effect of intumescent coatings is analyzed. A math. model is presented, which makes it possible to prognosticate the state of fireproofed constructions after being subjected to heat stress characteristic for fires. The theor. calcns. were in good agreement with exptl. results obtained for steel sample.
ST intumescent fireproofing coating heat mass transfer; math model fireproofing action intumescent coating
IT Intumescent materials
(fire-resistant coatings; modeling of heat and mass transfer in intumescent fire-resistant coatings)
IT Fire-resistant coatings
(intumescent; modeling of heat and mass transfer in intumescent fire-resistant coatings)

IT Heat transfer
Mass transfer
Physicochemical simulation
(modeling of heat and mass transfer in intumescent fire-resistant coatings)
IT 212384-33-3, OVR 1 212384-44-6, SGK 1 (coating)
RL: PEP (Physical, engineering or chemical process); PRP (Properties);
TEM
(Technical or engineered material use); PROC (Process); USES (Uses)
(modeling of heat and mass transfer in intumescent fire-resistant coatings)
IT 12597-69-2, Steel, properties
RL: PEP (Physical, engineering or chemical process); PRP (Properties);
PROC (Process)
(modeling of heat and mass transfer in intumescent fire-resistant coatings on)